Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer Beloud

Nationaltribune

@nationaltribune.com.au · 1 hour

Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer

Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer

Positive results from the Phase III SANOVO trial indicate that combining Tagrisso (osimertinib) with Orpathys (savolitinib) significantly improves progression-free survival for patients with...

Read more Nationaltribune.com.au